HE4, another biomarker that has been shown to aid CA125 in diagnosing and monitoring ovarian cancer and EC, was reported to predict the existence of lymph node metastasis (16), treatment response (20), and prognosis (21) of EC. This evidence concerns the gene WFDC2 and ovarian cancer.